Key Findings
Lonza, a leading Contract Development and Manufacturing Organization (CDMO), and Engitix Ltd., a specialist in extracellular matrix (ECM) biology, have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform. This strategic partnership aims to develop novel ADC-based therapies for cancer and fibrosis, specifically targeting components of the ECM. This collaboration provides Engitix with access to Lonza’s well-established and advanced ADC technology suite, which is expected to accelerate the development of innovative therapeutics with novel mechanisms of action.
Technical and Business Details
Under the terms of the agreement, Engitix will be able to utilize Lonza’s key ADC technology platforms:
- SYNtecan E Linker-Payload Technology: This represents a state-of-the-art linker technology for conjugating potent payloads to antibodies, optimizing the balance between stability and tumor-specific payload release.
- GlycoConnect Conjugation Technology: A site-specific conjugation technology that attaches payloads to specific glycan sites on the antibody. This enables the production of homogeneous ADCs with a consistent drug-to-antibody ratio (DAR), leading to improved reproducibility and stability. This offers significant advantages over traditional random conjugation methods, yielding more uniform and potentially safer ADCs.
- HydraSpace Polar Spacer Technology: This technology integrates polar spacers designed to improve the solubility and pharmacokinetic properties of ADCs, which can contribute to higher payload loading capacities or enhanced delivery efficiency to specific tissues.
Engitix plans to leverage these Lonza technologies to develop ADCs that specifically target components of the ECM. The ECM is known to play crucial roles in cancer progression, metastasis, drug resistance, and the pathophysiology of various fibrotic diseases. By targeting the ECM, these ADCs aim for specific drug delivery not only to cancer cells but also to cells involved in the tumor microenvironment and fibrosis, potentially enhancing therapeutic efficacy and reducing off-target side effects.
Background and Industry Context
ADCs are rapidly advancing as one of the most promising modalities in cancer therapy. However, their design and manufacturing require highly specialized expertise and sophisticated technologies. Lonza has been a leader in the CDMO space for ADCs, developing proprietary technology platforms over many years. Engitix, on the other hand, possesses deep expertise in ECM biology, enabling it to identify novel therapeutic targets in cancer and fibrosis. This collaboration is designed to combine the strengths of both companies to create groundbreaking treatments for complex diseases.
Strategic Significance and Outlook
This licensing agreement between Lonza and Engitix will significantly impact the development of next-generation ADCs. Lonza’s technologies, which enable the manufacturing of site-specific and homogeneous ADCs, are crucial for broadening the therapeutic window of ADCs and bringing safer, more effective drugs to market. The ECM-targeting approach holds promise not only for cancer therapy but also for developing novel treatments for fibrotic diseases such such as chronic kidney disease, liver cirrhosis, and idiopathic pulmonary fibrosis. This partnership is expected to further drive innovation in therapeutic development for disease areas with high unmet medical needs.
Source: https://www.biopharminternational.com/view/lonza-engitix-adc-deal-ecm-cancer-fibrosis
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments